Myelodysplastic Syndromes with Ring Sideroblasts
Research activity includes treatment of anemia in adults with lower-risk myelodysplastic syndromes, especially those with ring sideroblasts who depend on red blood cell transfusions and have limited response to prior erythropoiesis-stimulating agents.
- Transfusion-dependent anemia
- Red blood cell transfusion independence
- Lower-risk MDS
The sponsor’s work in this area centers on hematologic disease management and the clinical burden of chronic transfusion needs.
Higher-Risk MDS and Oligoblastic AML
Clinical research also addresses patients with higher-risk myelodysplastic syndromes and oligoblastic acute myeloid leukemia who are being prepared for allogeneic hematopoietic cell transplantation within a short treatment window.
- Pre-transplant disease control
- Allogeneic HCT
- Acute myeloid leukemia
This area reflects a focus on treatment pathways before transplant in aggressive myeloid malignancies.
Diffuse Large B-Cell Lymphoma
The sponsor funds research in relapsed or primary refractory diffuse large B-cell lymphoma, addressing patients whose disease has not responded adequately to prior therapy and who require second-line treatment options.
- Relapsed DLBCL
- Primary refractory lymphoma
- Salvage therapy
Its lymphoma portfolio is concentrated on aggressive B-cell malignancies with high unmet need in the relapsed setting.
